Email :
Contact : (321) 445-1969

Gastrointestinal Events Associated with Ipilimumab and combination therapies

Immunotherapy of cancer has made significant advances in the past few years mainly due to the improved understanding of underlying principles of tumor pathology and immunology. Currently many malignancies are being treated by immunotherapy. Including malignant melanoma, advanced renal cell carcinoma (RCC), Non-small cell lung cancer, and prostate cancer. In these malignancies targeted therapies like multi kinase inhibitors also play an important role. These therapies are not without significant adverse events. This article reviews gastrointestinal side effects reported with immunotherapeutic agents like ipilimumab, programmed death-1 (PD-1) antibody inhibitors and the multi-kinase inhibitor, pazopanib and their management. Awareness and education of Health care professionals (HCPs) and patients are critical in identifying and managing these adverse events. We have reviewed contemporary scientific literature and have summarized the results. Close monitoring and early treatment is of paramount importance in handling these event with the majority of events reversible or medically manageable per established treatment guidelines.

Download Pdf